Concerning the β-catenin independent branch of Wnt signaling, the expression of ROR1 almost exclusively in CLL cells and other lymphomas makes them relatively selective and attractive targets for the development of new antitumor drugs. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.